| Year |
Citation |
Score |
| 2018 |
Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nature Medicine. PMID 29808010 DOI: 10.1038/S41591-018-0022-X |
0.303 |
|
| 2016 |
Henderson L, Xu P, O'Day E, Cecchi F, Blackler A, Liao W, Hembrough TA, Catenacci DVT. KRAS gene amplification to define a distinct molecular subgroup of gastroesophageal adenocarcinoma. Journal of Clinical Oncology. 34: 4065-4065. DOI: 10.1200/Jco.2016.34.4_Suppl.74 |
0.303 |
|
| 2016 |
Chapman CG, Catenacci DV, Xu P, Koons A, Konda VJ, Siddiqui UD, Waxman I. 1106 EUS Acquired Portal Venous Circulating Tumor Cells (PV-CTCs) May Provide Prognostic Assistance in Pancreaticobiliary Cancers Gastroenterology. 150. DOI: 10.1016/S0016-5085(16)30821-6 |
0.303 |
|
| 2015 |
Catenacci DV, Liao WL, Zhao L, Whitcomb E, Henderson L, O'Day E, Xu P, Thyparambil S, Krizman D, Bengali K, Uzzell J, Darfler M, Cecchi F, Blackler A, Bang YJ, et al. Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. PMID 26581548 DOI: 10.1007/S10120-015-0566-0 |
0.308 |
|
| 2015 |
Catenacci DVT, Tang R, Oliner KS, Ang A, Loberg RD, O'Day E, Xu P, Henderson L, Ruzzo A, Graziano F. MET as a prognostic biomarker of survival in a large cohort of patients with gastroesophageal cancer (GEC). Journal of Clinical Oncology. 33: 4034-4034. DOI: 10.1200/Jco.2015.33.15_Suppl.4034 |
0.315 |
|
| 2014 |
Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, et al. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. Plos One. 9: e100586. PMID 24983965 DOI: 10.1371/Journal.Pone.0100586 |
0.329 |
|
| 2014 |
Catenacci DVT, Polite BN, Henderson L, Xu P, Rambo B, Liao W, Hembrough TA, Zhao L, Xiao S, Hart J, Karrison T, Dignam JJ, Kindler HL. Toward personalized treatment for gastroesophageal adenocarcinoma (GEC): Strategies to address tumor heterogeneity—PANGEA. Journal of Clinical Oncology. 32: 66-66. DOI: 10.1200/Jco.2014.32.3_Suppl.66 |
0.313 |
|
| 2014 |
Hembrough TA, Henderson L, Rambo B, Liao W, Thyparambil S, Bangali K, Uzzell J, Darfler M, Krizman D, Xu P, Xiao S, Zhao L, Burrows J, Catenacci DVT. Quantification of HER2 from gastroesophageal cancer (GEC) FFPE tissue by mass spectrometry (MS). Journal of Clinical Oncology. 32: 17-17. DOI: 10.1200/Jco.2014.32.3_Suppl.17 |
0.316 |
|
| 2014 |
Hembrough TA, Liao W, Thyparambil S, Henderson L, Rambo B, Cecchi F, Bottaro DP, Darfler M, Xu P, Xiao S, Zhao L, Veenstra TD, Burrows J, Catenacci DVT. Quantification of MET expression using mass spectrometry (MS): Assay precision and stability in FFPE tumor tissue. Journal of Clinical Oncology. 32: 16-16. DOI: 10.1200/Jco.2014.32.3_Suppl.16 |
0.304 |
|
| 2014 |
Cecchi F, Liao W, Thyparambil S, Bengali K, Uzzell J, Darflar M, Krizman D, Burrows J, Hembrough T, Veenstra T, Bottaro D, Karrison T, Henderson L, Xu P, Rambo B, et al. 537 Absolute quantitation of MET using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue European Journal of Cancer. 50: 175. DOI: 10.1016/S0959-8049(14)70663-X |
0.302 |
|
| 2013 |
Hembrough T, Liao W, Henderson L, Xu P, Thyparambil S, Burrows J, Catenacci DV. Abstract 41: Development of a quantitative colorectal cancer SRM assay for use in FFPE tumor tissues. Cancer Research. 73: 41-41. DOI: 10.1158/1538-7445.Am2013-41 |
0.369 |
|
| 2013 |
Catenacci DV, Xu P, Henderson L, Liao W, Thyparambil S, Burrows J, Hembrough T. Abstract 1207: Development of a quantitative gastroesophageal cancer selected reaction monitoring mass Spectrometric Multiplex Assay for use in FFPE tumor tissues. Cancer Research. 73: 1207-1207. DOI: 10.1158/1538-7445.Am2013-1207 |
0.358 |
|
| 2012 |
Hembrough T, Liao W, Henderson L, Xu P, Burrows J, Catenacci D. Abstract A50: Development of a quantitative RON SRM Assay for use in formalin fixed tumor tissues Clinical Cancer Research. 18: A50-A50. DOI: 10.1158/1078-0432.Mechres-A50 |
0.354 |
|
| 2012 |
Catenacci D, Xu P, Henderson L, Liao W, Burrows J, Hembrough T. 561 Development of a Quantitative Gastroesophageal Cancer Selected Reaction Monitoring Mass Spectrometric Multiplex Assay for Use in FFPE Tumor Tissues European Journal of Cancer. 48: 172. DOI: 10.1016/S0959-8049(12)72358-4 |
0.309 |
|
| 2012 |
Hembrough T, Henderson L, Xu P, Liao W, Burrows J, Catenacci D. 483 Development of a Quantitative Colorectal Cancer SRM Assay for Use in FFPE Tumor Tissues European Journal of Cancer. 48: 150. DOI: 10.1016/S0959-8049(12)72281-5 |
0.313 |
|
| Show low-probability matches. |